Relebactam
- Generic Name
- Relebactam
- Brand Names
- Recarbrio
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N4O6S
- CAS Number
- 1174018-99-5
- Unique Ingredient Identifier
- 1OQF7TT3PF
- Background
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, ...
- Indication
Relebactam is indicated in combination with imipenem and cilastatin for the treatment of complicated urinary tract infections (including pyelonephritis), and complicated intra-abdominal infections caused by susceptible organisms in adults.
- Associated Conditions
- Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Pyelonephritis
- Associated Therapies
- -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath